Company intelligence / Profile preview

SteroTherapeutics

Doylestown, Pennsylvania, United Statessterotx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company has advanced its lead candidate ST‑002 into a Phase II trial for Cushing’s syndrome and received orphan drug designation from the FDA. Preclinical and early human studies have shown favorable safety profiles and established mechanisms of action. Additional programs target NASH and PSC, both with significant unmet needs.

Therapeutic areas: GastroenterologyOncologyEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

ST-004

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

National Institutes of Health / NIH CRADA agreement for Cushing's program

Beyond the preview

Go deeper on SteroTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SteroTherapeutics.

Explore the full profile